Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

Also called NCT04282941

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04282941
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04282941. Randomized; double masking; primary purpose treatment. Start 2017-02-20 (actual); primary completion 2020-01-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis
Acronym
IBU24h-EchoG
Condition
Persistent Ductus Arteriosus
Intervention (Drug)
Ibuprofen in continuous (24 hours) iv infusion and EchoG
Intervention (Drug)
IV bolus Ibuprofen slow (15 minutes) and EchoG
Lead sponsor
Instituto de Investigación Hospital Universitario La Paz (class: other)

Record details

Record id
cardio:ct-nct04282941
Content hash
5f66547380db32282d4baa8fc67dc72ff10af2ca3e907170b6e1b91b4975abea